

Stuart Rich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10583289/publications.pdf>

Version: 2024-02-01

98
papers

22,043
citations

23567

58
h-index

37204

96
g-index

100
all docs

100
docs citations

100
times ranked

8265
citing authors

#	ARTICLE	IF	CITATIONS
1	Are anticoagulants still indicated in pulmonary arterial hypertension?. Pulmonary Circulation, 2018, 8, 1-5.	1.7	11
2	Pulmonary hypertension: the unaddressed global health burden. Lancet Respiratory Medicine, the, 2018, 6, 577-579.	10.7	28
3	Tricuspid regurgitation progression and regression in pulmonary arterial hypertension: implications for right ventricular and tricuspid valve apparatus geometry and patients outcome. European Heart Journal Cardiovascular Imaging, 2017, 18, 86-94.	1.2	61
4	Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 464-475.	5.6	69
5	Peripheral Blood Signature of Vasodilator-Responsive Pulmonary Arterial Hypertension. Circulation, 2015, 131, 401-409.	1.6	72
6	Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults. Chest, 2014, 146, 449-475.	0.8	237
7	Clinical Diagnosis of Pulmonary Hypertension. Circulation, 2014, 130, 1820-1830.	1.6	100
8	Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2013, 62, D51-D59.	2.8	432
9	The Pulmonary Hypertension Academic Research Consortium. Pulmonary Circulation, 2013, 3, 203-205.	1.7	3
10	Noninvasive cardiac output measurements in patients with pulmonary hypertension. European Respiratory Journal, 2013, 42, 125-133.	6.7	59
11	What is Pulmonary Arterial Hypertension?. Pulmonary Circulation, 2012, 2, 271-272.	1.7	17
12	The Importance of Sex in Pulmonary Hypertension. Chest, 2012, 141, 4-5.	0.8	3
13	Right Ventricular Adaptation and Maladaptation in Chronic Pulmonary Arterial Hypertension. Cardiology Clinics, 2012, 30, 257-269.	2.2	44
14	The 6-Minute Walk Test as a Primary Endpoint in Clinical Trials for Pulmonary Hypertension. Journal of the American College of Cardiology, 2012, 60, 1202-1203.	2.8	34
15	Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension. Histopathology, 2012, 61, 597-609.	2.9	34
16	Future of Clinical Trials for Pulmonary Hypertension. Circulation, 2011, 123, 2919-2921.	1.6	7
17	Clinical Characteristics of Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure, 2011, 4, 257-265.	3.9	253
18	Inaccuracy of Doppler Echocardiographic Estimates of Pulmonary Artery Pressures in Patients With Pulmonary Hypertension. Chest, 2011, 139, 988-993.	0.8	328

#	ARTICLE	IF	CITATIONS
19	Calcium Channel Blockers in the Treatment of Pulmonary Arterial Hypertension. , 2011, , 1447-1450.		0
20	Long-term Effects of Epoprostenol on the Pulmonary Vasculature in Idiopathic Pulmonary Arterial Hypertension. Chest, 2010, 138, 1234-1239.	0.8	109
21	Targeting Pulmonary Vascular Disease To Improve Global Health. Chest, 2010, 137, 1S-5S.	0.8	11
22	Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2010, 29, 181-187.	0.6	62
23	Systematic review of trials using vasodilators in pulmonary arterial hypertension: Why a new approach is needed. American Heart Journal, 2010, 159, 245-257.	2.7	106
24	The Effects of Vasodilators in Pulmonary Hypertension. Circulation: Heart Failure, 2009, 2, 145-150.	3.9	27
25	Selective Serotonin Reuptake Inhibitors and the Incidence and Outcome of Pulmonary Hypertension. Chest, 2009, 136, 694-700.	0.8	42
26	Clinical Implications of Determining BMPR2 Mutation Status in a Large Cohort of Children and Adults With Pulmonary Arterial Hypertension. Journal of Heart and Lung Transplantation, 2008, 27, 668-674.	0.6	157
27	Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1 α -Kv1.5 O ₂ -sensing pathway at the intersection of pulmonary hypertension and cancer. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H570-H578.	3.2	319
28	Uncertainties in the Diagnosis and Treatment of Pulmonary Arterial Hypertension. Circulation, 2008, 118, 1195-1201.	1.6	90
29	Association of Serum Creatinine With Abnormal Hemodynamics and Mortality in Pulmonary Arterial Hypertension. Circulation, 2008, 117, 2475-2483.	1.6	116
30	Diagnosis and Treatment of Secondary (Non-Category 1) Pulmonary Hypertension. Circulation, 2008, 118, 2190-2199.	1.6	95
31	How Do We Explain Unexplained Pulmonary Hypertension in the Elderly?. Chest, 2007, 131, 5-6.	0.8	5
32	Temporal trends and drug exposures in pulmonary hypertension: An American experience. American Heart Journal, 2006, 152, 521-526.	2.7	78
33	The Current Treatment of Pulmonary Arterial Hypertension. Chest, 2006, 130, 1198-1202.	0.8	83
34	Relationship of <i>BMPR2</i> Mutations to Vasoreactivity in Pulmonary Arterial Hypertension. Circulation, 2006, 113, 2509-2515.	1.6	136
35	Efficacy and Safety of Sildenafil Added to Treprostinil in Pulmonary Hypertension. American Journal of Cardiology, 2005, 96, 1334-1336.	1.6	88
36	Pulmonary hypertension. Current Problems in Cardiology, 2004, 29, 575-634.	2.4	17

#	ARTICLE	IF	CITATIONS
37	Clinical classification of pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S5-S12.	2.8	1,542
38	Treprostinil, a Prostacyclin Analogue, in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. <i>Chest</i> , 2004, 126, 420-427.	0.8	232
39	Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary pulmonary hypertension. <i>American Journal of Cardiology</i> , 2003, 92, 1366-1368.	1.6	23
40	Beraprost therapy for pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2003, 41, 2119-2125.	2.8	563
41	Endothelin Receptor Blockers in Cardiovascular Disease. <i>Circulation</i> , 2003, 108, 2184-2190.	1.6	205
42	Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 41, 293-299.	1.9	219
43	Survival in Primary Pulmonary Hypertension. <i>Circulation</i> , 2002, 106, 1477-1482.	1.6	1,092
44	Electron Beam Computed Tomography for Assessment of Coronary Artery Disease in HIV-Infected Men Receiving Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 30, 191-195.	2.1	42
45	Clinical Efficacy of Sitaxsentan, an Endothelin-A Receptor Antagonist, in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2002, 121, 1860-1868.	0.8	214
46	Detection of Subclinical Cardiovascular Disease: The Emerging Role of Electron Beam Computed Tomography. <i>Preventive Medicine</i> , 2002, 34, 1-10.	3.4	34
47	Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. <i>American Heart Journal</i> , 2002, 143, 4A-10A.	2.7	68
48	Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 800-804.	5.6	1,288
49	A New Classification of Pulmonary Hypertension. <i>Advances in Pulmonary Hypertension</i> , 2002, 1, 3-6.	0.1	5
50	SEVERE PULMONARY HYPERTENSION: CRITICAL CARE CLINICS. <i>Critical Care Clinics</i> , 2001, 17, 453-467.	2.6	8
51	Stenting To Reverse Left Ventricular Ischemia Due To Left Main Coronary Artery Compression in Primary Pulmonary Hypertension. <i>Chest</i> , 2001, 120, 1412-1415.	0.8	60
52	Age and gender distributions of coronary artery calcium detected by electron beam tomography in 35,246 adults. <i>American Journal of Cardiology</i> , 2001, 87, 1335-1339.	1.6	401
53	Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease. <i>Annals of Internal Medicine</i> , 2000, 132, 425.	3.9	905
54	Primary pulmonary hypertension. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2000, 2, 135-139.	0.9	15

#	ARTICLE	IF	CITATIONS
55	Anorexigens and Pulmonary Hypertension in the United States. <i>Chest</i> , 2000, 117, 870-874.	0.8	183
56	Primary Pulmonary Hypertension. <i>Circulation</i> , 2000, 102, 2781-2791.	1.6	340
57	The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 1999, 34, 1184-1187.	2.8	175
58	Development of Nonspecific Interstitial Pneumonitis Associated With Long-term Treatment of Primary Pulmonary Hypertension With Prostacyclin. <i>Chest</i> , 1999, 116, 566-569.	0.8	20
59	Lung transplantation for pulmonary hypertension: patient selection and maintenance therapy while awaiting transplantation. <i>Transplantation Reviews</i> , 1998, 12, 205-208.	2.9	0
60	Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 1998, 338, 273-277.	27.0	639
61	Lung Transplantation for Pulmonary Hypertension: Patient Selection and Maintenance Therapy While Awaiting Transplantation. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 1998, 10, 135-138.	0.6	7
62	The Short-term Effects of Digoxin in Patients With Right Ventricular Dysfunction From Pulmonary Hypertension. <i>Chest</i> , 1998, 114, 787-792.	0.8	322
63	Clinical Insights Into the Pathogenesis of Primary Pulmonary Hypertension. <i>Chest</i> , 1998, 114, 237S-241S.	0.8	47
64	Relation between hormone replacement therapy in women and coronary artery disease estimated by electron beam tomography. <i>American Heart Journal</i> , 1997, 134, 1115-1119.	2.7	19
65	Usefulness of Atrial Septostomy as a Treatment for Primary Pulmonary Hypertension and Guidelines for its Application. <i>American Journal of Cardiology</i> , 1997, 80, 369-371.	1.6	94
66	Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension. <i>Circulation</i> , 1997, 95, 1479-1486.	1.6	271
67	Serum nifedipine concentrations and response of patients with pulmonary hypertension. <i>American Journal of Cardiology</i> , 1996, 77, 996-999.	1.6	7
68	Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 1996, 335, 609-616.	27.0	1,127
69	A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 1996, 334, 296-301.	27.0	2,529
70	Ultrafast Computed Tomography as a Diagnostic Modality in the Detection of Coronary Artery Disease. <i>Circulation</i> , 1996, 93, 898-904.	1.6	434
71	The Cellular Basis of the Pathophysiology and Treatment of Pulmonary Hypertension. , 1996, , 175-180.		0
72	Comparative Acute Effects of Adenosine and Prostacyclin in Primary Pulmonary Hypertension. <i>Chest</i> , 1995, 107, 54-57.	0.8	88

#	ARTICLE	IF	CITATIONS
73	Medical treatment of primary pulmonary hypertension: A bridge to transplantation?. American Journal of Cardiology, 1995, 75, 63A-66A.	1.6	38
74	Understanding right and left ventricular systolic function and interactions at rest and with exercise in primary pulmonary hypertension. American Journal of Cardiology, 1995, 75, 374-377.	1.6	78
75	Reproducibility of the measurement of coronary calcium with ultrafast computed tomography. American Journal of Cardiology, 1995, 75, 973-975.	1.6	136
76	Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: Relation to hemodynamic variables and endothelin levels. Journal of the American College of Cardiology, 1995, 26, 1581-1585.	2.8	281
77	Pressure and Volume Loading of the Right Ventricle Have Opposite Effects on Left Ventricular Ejection Fraction. Circulation, 1995, 92, 819-824.	1.6	146
78	Prostacyclin and Primary Pulmonary Hypertension. Annals of Internal Medicine, 1994, 121, 463.	3.9	5
79	The Medical Treatment of Primary Pulmonary Hypertension. Chest, 1994, 105, 17S-20S.	0.8	16
80	Successful management of labor and delivery in primary pulmonary hypertension. American Journal of Cardiology, 1993, 71, 1124-1125.	1.6	35
81	Short-term effectiveness of nifedipine in secondary pulmonary hypertension. American Journal of Cardiology, 1993, 71, 1475-1476.	1.6	15
82	Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension. Journal of the American College of Cardiology, 1993, 21, 413-418.	2.8	38
83	The Role of Thrombosis in Pulmonary Hypertension. Chest, 1993, 103, 660-661.	0.8	11
84	The Prevalence and Significance of a Patent Foramen Ovale in Pulmonary Hypertension. Chest, 1993, 104, 1673-1675.	0.8	57
85	The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension. New England Journal of Medicine, 1992, 327, 76-81.	27.0	1,469
86	Doppler echocardiographic demonstration of the differential effects of right ventricular pressure and volume overload on left ventricular geometry and filling. Journal of the American College of Cardiology, 1992, 19, 84-90.	2.8	137
87	Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. Journal of the American College of Cardiology, 1992, 19, 1060-1064.	2.8	90
88	Autoantibodies in patients with primary pulmonary hypertension: Association with anti-Ku. American Journal of Medicine, 1992, 93, 307-312.	1.5	112
89	High dose titration of calcium channel blocking agents for primary pulmonary hypertension: Guidelines for short-term drug testing. Journal of the American College of Cardiology, 1991, 18, 1323-1327.	2.8	84
90	Familial Pulmonary Hypertension in Association with an Abnormal Hemoglobin. Chest, 1991, 99, 1208-1210.	0.8	24

#	ARTICLE	IF	CITATIONS
91	The Effects of Phenylephrine on Right Ventricular Performance in Patients with Pulmonary Hypertension. <i>Chest</i> , 1990, 98, 1102-1106.	0.8	80
92	The Acute Administration of Vasodilators in Primary Pulmonary Hypertension: Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. <i>The American Review of Respiratory Disease</i> , 1989, 140, 1623-1630.	2.9	177
93	Primary pulmonary hypertension. <i>Progress in Cardiovascular Diseases</i> , 1988, 31, 205-238.	3.1	142
94	Primary Pulmonary Hypertension. <i>Annals of Internal Medicine</i> , 1987, 107, 216.	3.9	1,811
95	Doppler echocardiography assessment of impaired left ventricular filling in patients with right ventricular pressure overload due to primary pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 1986, 8, 1298-1306.	2.8	175
96	Primary Pulmonary Hypertension: Radiographic and Scintigraphic Patterns of Histologic Subtypes. <i>Annals of Internal Medicine</i> , 1986, 105, 499.	3.9	75
97	Magnitude and implications of spontaneous hemodynamic variability in primary pulmonary hypertension. <i>American Journal of Cardiology</i> , 1985, 55, 159-163.	1.6	125
98	Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension. <i>American Journal of Medicine</i> , 1984, 76, 573-578.	1.5	108